Resumo

POLITEI, Juan Manuel; SCHENONE, Andrea B; DURAND, Consuelo  e  ORTIZ, Alberto. ENZYME REPLACEMENT THERAPY IN FABRY DISEASE: THE IMPORTANCE OF DOSE. Rev. nefrol. dial. traspl. [online]. 2015, vol.35, n.4, pp.220-228. ISSN 2346-8548.

Fabry disease is a rare X-linked inherited disorder due to deficient or absent lysosomal a-galactosidase A activity, resulting in an excessive glycosphingolipid deposit, mainly globotriaosylceramide (gl3) and mortality due renal, cardiac and neurological cause. Current treatment available is enzyme replacement therapy, where the deficient enzyme is substituted. In Latinamerica and Europe two different formulations of agalsidase (alfa and beta) are available. Food and Drug Administration in United States did not approve agalsidasa Alfa. The main difference among these formulations is the licensed dose: 0.2 mg/kg every other week for Alfa and 1 mg/kg every other week for Beta. Recent studies suggest a dose-dependent response, making 0.2 mg/kg every other week not sufficient in some patients. However there are no tools to predict which patients need a higher dose for preventing or decreasing the disease progression. This review, summarize the current knowledge about the impact of different dose and its efficacy in Fabry disease.

Palavras-chave : agalsidase; Fabry disease; enzyme replacement therapy.